摘要
表皮生长因子受体抑制剂(EGFRIs)已经证明改善非小细胞肺癌,胰腺癌,大肠癌患者的总生存期,靶向药物耐受性好,通常出现轻微或中度的毒副反应。尽管大多数不良反应是可以得到迅速处理的,但是严重的甚至危及生命的不良反应仍能够发生,其中最常见的是皮肤不良反应,了解其副作用的病理基础,以便能够制定良好的治疗方案。
Epidermal growth factor receptor inhibitors （EGFRIs） have been demonstrated to improve the overall survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Generally, they are well tolerated, toxicities are commonly mild to moderate and can be handled rapidly. However, serious, even life-threatening side effects still occurs, and the adverse reaction in skin is one of the most common side effects. It is important to understand the pathological basis of the side effects for the prevention.
出处
《皮肤病与性病》
2012年第5期271-273,288,共4页
Dermatology and Venereology
关键词
表皮生长因子受体抑制剂
靶向治疗
皮肤不良反应
Epidermal growth factor receptor inhibitors
Targeted therapy
Side response
Skin
